Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.58 +1.4%	$3.30	$2.71 ▼ $4.73	$685.67M	1.23	967,306 shs	751,939 shs
ALTS Janone	$9.50 -7.4%	$6.85	$1.29 ▼ $11.12	$165.82M	2.31	229,023 shs	218,673 shs
GHRS GH Research	$12.72 -0.3%	$10.73	$6.00 ▼ $20.50	$661.80M	0.97	188,795 shs	229,125 shs
SANA Sana Biotechnology	$2.52 -2.7%	$1.96	$1.26 ▼ $7.40	$568.20M	1.78	3.55 million shs	2.37 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	+1.44%	+14.61%	+7.62%	+12.42%
ALTS Janone	0.00%	+0.49%	+50.88%	+126.99%	+1,025,999,900.00%
GHRS GH Research	0.00%	+2.08%	+16.21%	+19.81%	+6.42%
SANA Sana Biotechnology	0.00%	-8.80%	+48.42%	-6.50%	-57.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.2484 of 5 stars	3.5	0.0	0.0	0.0	3.2	2.5	0.6
ALTS Janone	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	1.7891 of 5 stars	3.5	0.0	0.0	0.0	2.9	2.5	0.0
SANA Sana Biotechnology	1.9273 of 5 stars	3.4	0.0	0.0	0.0	1.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	53.63% Upside
ALTS Janone	0.00	N/A	N/A	N/A
GHRS GH Research	3.00	Buy	$32.00	151.57% Upside
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	328.57% Upside

Current Analyst Ratings Breakdown

Latest ALTS, ABUS, GHRS, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
5/13/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $29.00
5/9/2025	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/18/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/18/2025	SANA Sana Biotechnology	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$5.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.40M	107.09	N/A	N/A	$0.63 per share	5.68
ALTS Janone	$18.05M	9.19	N/A	N/A	($0.67) per share	-14.18
GHRS GH Research	N/A	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$72.85M	-$0.41	N/A	N/A	N/A	-1,137.65%	-68.18%	-51.55%	7/30/2025 (Estimated)
ALTS Janone	-$7.81M	N/A	0.00	∞	N/A	N/A	-2,940.01%	-39.81%	N/A
GHRS GH Research	-$35.59M	-$0.79	N/A	N/A	N/A	N/A	-20.29%	-19.49%	9/2/2025 (Estimated)
SANA Sana Biotechnology	-$283.26M	-$0.88	N/A	N/A	N/A	N/A	-84.22%	-44.97%	8/6/2025 (Estimated)

Latest ALTS, ABUS, GHRS, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million
3/17/2025	Q4 2024	SANA Sana Biotechnology	-$0.25	-$0.23	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ALTS Janone	$1.22	12.84%	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	7.02	7.02
ALTS Janone	1.96	0.75	0.75
GHRS GH Research	N/A	15.83	15.83
SANA Sana Biotechnology	N/A	4.47	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ALTS Janone	6.27%
GHRS GH Research	56.90%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
ALTS Janone	4.90%
GHRS GH Research	41.60%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	181.91 million	Optionable
ALTS Janone	170	17.46 million	13.38 million	N/A
GHRS GH Research	10	52.03 million	30.38 million	Optionable
SANA Sana Biotechnology	380	225.48 million	153.83 million	Optionable

ALTS, ABUS, GHRS, and SANA Headlines

Recent News About These Companies

Sana Biotechnology (NASDAQ:SANA) Trading Down 7.2% - Here's Why

June 11, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 8.3% - What's Next?

June 10, 2025 | marketbeat.com

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

June 9, 2025 | globenewswire.com

Two Sigma Investments LP Grows Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

June 8, 2025 | marketbeat.com

Biggest Stocks in NASDAQ Featuring Sana Biotechnology and Kalkine

June 7, 2025 | kalkinemedia.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Position Raised by Two Sigma Advisers LP

June 6, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Millennium Management LLC

June 5, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Up 10.9% - Time to Buy?

June 4, 2025 | marketbeat.com

Bank of America Corp DE Increases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

June 4, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Sold by Voloridge Investment Management LLC

May 31, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

May 29, 2025 | marketbeat.com

Jane Street Group LLC Boosts Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

May 29, 2025 | marketbeat.com

Sana Biotechnology to Present at June 2025 Investor Conferences

May 28, 2025 | globenewswire.com

Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025

May 20, 2025 | accessnewswire.com

SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 20, 2025 | globenewswire.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

May 20, 2025 | tmcnet.com

Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky

May 20, 2025 | accessnewswire.com

SANA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA

May 20, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA

May 20, 2025 | prnewswire.com

Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025

May 20, 2025 | accessnewswire.com

SANA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

May 20, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALTS, ABUS, GHRS, and SANA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.58 +0.05 (+1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$3.58 0.00 (0.00%)

As of 04:13 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Janone NASDAQ:ALTS

$9.50 -0.76 (-7.41%)

Closing price 04:00 PM Eastern

Extended Trading

$9.75 +0.25 (+2.63%)

As of 04:39 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

GH Research NASDAQ:GHRS

$12.72 -0.04 (-0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$12.82 +0.09 (+0.75%)

As of 04:04 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Sana Biotechnology NASDAQ:SANA

$2.52 -0.07 (-2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$2.56 +0.04 (+1.39%)

As of 04:20 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time